TapewireFind a company

person · Reporting owner

Durso Jerome Benedict

Disclosed activity across 2 companies

Tapewire entity
23679
SEC CIK
0001698665

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Altimmune, Inc.ALT · Entity 5349Director · President and CEOAugust 13, 2026August 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Altimmune, Inc.

Report date August 13, 2026 · Filed August 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.0001SEC Table I · non-derivativeDirect62,500 Reported balance After 2026-08-13 transaction · row 1
1 source row

Row 1 · 2026-08-13 · Purchase · Acquired 15,000 · Balance 62,500

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

INTERCEPT PHARMACEUTICALS, INC.

Report date November 08, 2023 · Filed November 13, 2023

Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-11-08 transaction · row 1 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 1 · 2023-11-08 · Other · Disposed 51,815 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-11-08 transaction · row 2 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 2 · 2023-11-08 · Disposition to issuer · Disposed 102,825 · Balance 0

F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.44Direct0 Reported balance After 2023-11-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-11-08 · Disposition to issuer · Disposed 60,900 · Balance 0

F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.40Direct0 Reported balance After 2023-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-11-08 · Disposition to issuer · Disposed 82,700 · Balance 0

F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.93Direct0 Reported balance After 2023-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-11-08 · Disposition to issuer · Disposed 3,419 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.93Direct0 Reported balance After 2023-11-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2023-11-08 · Disposition to issuer · Disposed 16,581 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74Direct0 Reported balance After 2023-11-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2023-11-08 · Disposition to issuer · Disposed 71 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74Direct0 Reported balance After 2023-11-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2023-11-08 · Disposition to issuer · Disposed 20,629 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80Direct0 Reported balance After 2023-11-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2023-11-08 · Disposition to issuer · Disposed 896 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80Direct0 Reported balance After 2023-11-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2023-11-08 · Disposition to issuer · Disposed 14,304 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $99.66Direct0 Reported balance After 2023-11-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2023-11-08 · Disposition to issuer · Disposed 17,400 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $29.46Direct0 Reported balance After 2023-11-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2023-11-08 · Disposition to issuer · Disposed 72,000 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 13, 2026 Filed Aug 13, 2026 20:05 UTC Altimmune, Inc. ALT · Entity 5349 PurchaseCommon Stock, par value $0.0001 15,000 $2.95 $44,250.00
Disclosure

SEC source: 0001698665-26-000007 · form4-08132026_040801.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

Read SEC document
April 01, 2026 Filed Apr 1, 2026 20:05 UTC Altimmune, Inc. ALT · Entity 5349 PurchaseCommon Stock, par value $0.0001 15,000 $3.14 $47,100.00
Disclosure

SEC source: 0001698665-26-000005 · form4-04012026_040404.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,500

Read SEC document
March 06, 2026 Filed Mar 9, 2026 11:00 UTC Altimmune, Inc. ALT · Entity 5349 PurchaseCommon Stock, par value $0.0001 20,000 $3.54 $70,790.00
Disclosure

SEC source: 0001698665-26-000003 · form4-03092026_070301.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.5300 to $3.5500, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
December 22, 2025 Filed Dec 22, 2025 21:10 UTC Altimmune, Inc. ALT · Entity 5349 PurchaseCommon Stock, par value $0.0001 12,500 $4.13 $51,568.75
Disclosure

SEC source: 0001698665-25-000005 · form4-12222025_091234.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.1200 to $4.1300, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote

Read SEC document
December 01, 2025 Filed Dec 2, 2025 01:38 UTC Altimmune, Inc. ALT · Entity 5349 GrantRestricted Stock Units · Derivative 633,700 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-117451 · tm2532516-1_4seq1.xml · derivative · entry 2

Durso Jerome Benedict · CIK 0001698665 · Director · CEO-elect

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 633,700

Underlying: Common Stock, par value $0.0001 · 633,700 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting December 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting December 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 01:38 UTC Altimmune, Inc. ALT · Entity 5349 GrantStock Options (option to buy) · Derivative 1,824,400 $0.00 Strike: $4.93 $0.00
Disclosure

SEC source: 0001104659-25-117451 · tm2532516-1_4seq1.xml · derivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · CEO-elect

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,824,400

Underlying: Common Stock, par value $0.0001 · 1,824,400 shares

Expires 2035-12-01

F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on December 1, 2026, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.

Read SEC document
September 25, 2025 Filed Sep 29, 2025 20:20 UTC Altimmune, Inc. ALT · Entity 5349 GrantStock Options (option to buy) · Derivative 48,800 $0.00 Strike: $3.92 $0.00
Disclosure

SEC source: 0001104659-25-094499 · tm2527377-8_4seq1.xml · derivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,800

Underlying: Common Stock, par value $0.0001 · 48,800 shares

Expires 2035-09-25

F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 25, 2025, subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
February 24, 2025 Filed Feb 25, 2025 22:46 UTC Altimmune, Inc. ALT · Entity 5349 GrantStock Options (option to buy) · Derivative 69,800 $0.00 Strike: $6.11 $0.00
Disclosure

SEC source: 0001104659-25-017006 · tm257585-3_4seq1.xml · derivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,800

Underlying: Common Stock, par value $0.0001 · 69,800 shares

Expires 2035-02-24

F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in 36 substantially equal monthly installments following February 24, 2025 subject to the reporting person's continued service through the applicable vesting date.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 72,000 Not disclosed Strike: $29.46 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 12

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 72,000 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 17,400 Not disclosed Strike: $99.66 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 11

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,400 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 14,304 Not disclosed Strike: $110.80 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 10

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,304 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 896 Not disclosed Strike: $110.80 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 9

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 896 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 20,629 Not disclosed Strike: $58.74 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 8

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,629 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 71 Not disclosed Strike: $58.74 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 7

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 71 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 16,581 Not disclosed Strike: $115.93 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 6

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,581 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 3,419 Not disclosed Strike: $115.93 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 5

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,419 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 82,700 Not disclosed Strike: $18.40 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 4

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 82,700 shares

Expires not disclosed

F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 60,900 Not disclosed Strike: $14.44 Not disclosed
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · derivative · entry 3

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,900 shares

Expires not disclosed

F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerCommon Stock 102,825 $19.00 $1,953,675.00
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · nonDerivative · entry 2

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:40 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 OtherCommon Stock 51,815 $19.00 $984,485.00
Disclosure

SEC source: 0001104659-23-117096 · tm2330435-7_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

Read SEC document
January 27, 2023 Filed Jan 31, 2023 16:04 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantOption to Purchase Common Stock · Derivative 82,700 $0.00 Strike: $18.40 $0.00
Disclosure

SEC source: 0001104659-23-008582 · tm234878-2_4seq1.xml · derivative · entry 2

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,700

Underlying: Common Stock · 82,700 shares

Expires 2033-01-27

F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023.

Read SEC document
January 27, 2023 Filed Jan 31, 2023 16:04 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 50,400 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-008582 · tm234878-2_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,640

F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023.

Read SEC document
December 31, 2022 Filed Jan 3, 2023 16:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 7,083 $12.37 $87,616.71
Disclosure

SEC source: 0001104659-23-000329 · tm231319-2_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,240

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
January 27, 2022 Filed Jan 31, 2022 16:14 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantOption to Purchase Common Stock · Derivative 60,900 $0.00 Strike: $14.44 $0.00
Disclosure

SEC source: 0001104659-22-009555 · tm224882-4_4seq1.xml · derivative · entry 2

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,900

Underlying: Common Stock · 60,900 shares

Expires 2032-01-27

F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022.

Read SEC document
January 27, 2022 Filed Jan 31, 2022 16:14 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 35,700 $0.00 $0.00
Disclosure

SEC source: 0001104659-22-009555 · tm224882-4_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,323

F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022.

Read SEC document
January 01, 2022 Filed Jan 4, 2022 16:16 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 334 $16.29 $5,440.86
Disclosure

SEC source: 0001104659-22-000917 · tm221409d2_4.xml · nonDerivative · entry 2

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,623

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 16:16 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 5,607 $16.29 $91,338.03
Disclosure

SEC source: 0001104659-22-000917 · tm221409d2_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,957

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
October 01, 2021 Filed Oct 5, 2021 17:28 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 289 $15.22 $4,398.58
Disclosure

SEC source: 0001104659-21-123209 · tm2129255d1_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,564

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
July 01, 2021 Filed Jul 2, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 289 $20.47 $5,915.83
Disclosure

SEC source: 0001104659-21-089031 · tm2121399-1_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,853

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
April 01, 2021 Filed Apr 5, 2021 19:02 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 289 $24.28 $7,016.92
Disclosure

SEC source: 0001104659-21-046699 · tm2111402-3_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,142

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
February 23, 2021 Filed Feb 25, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 319 $28.12 $8,970.28
Disclosure

SEC source: 0001104659-21-028419 · tm218010-1_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,431

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantOption to Purchase Common Stock · Derivative 72,000 $0.00 Strike: $29.46 $0.00
Disclosure

SEC source: 0001104659-21-007777 · tm214232-2_4seq1.xml · derivative · entry 2

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,000

Underlying: Common Stock · 72,000 shares

Expires 2031-01-22

F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 46,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-21-007777 · tm214232-2_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,750

F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2021.

Read SEC document
January 01, 2021 Filed Jan 5, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 334 $24.70 $8,249.80
Disclosure

SEC source: 0001104659-21-001120 · tm211606-2_4seq1.xml · nonDerivative · entry 2

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,750

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
December 31, 2020 Filed Jan 5, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 1,700 $24.70 $41,990.00
Disclosure

SEC source: 0001104659-21-001120 · tm211606-2_4seq1.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,084

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
November 23, 2020 Filed Nov 25, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 319 $35.47 $11,314.93
Disclosure

SEC source: 0001104659-20-129687 · tm2037136-1_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,784

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 19:02 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 289 $42.08 $12,161.12
Disclosure

SEC source: 0001104659-20-112321 · tm2032461d6_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,103

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
August 23, 2020 Filed Aug 25, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 319 $48.21 $15,378.99
Disclosure

SEC source: 0001104659-20-098460 · tm2029378d1_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,392

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
July 01, 2020 Filed Jul 6, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 289 $46.52 $13,444.28
Disclosure

SEC source: 0001104659-20-081430 · tm2024073d1_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,711

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
May 23, 2020 Filed May 27, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 319 $80.51 $25,682.69
Disclosure

SEC source: 0001104659-20-066534 · tm2020981d1_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
April 01, 2020 Filed Apr 3, 2020 19:02 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 289 $58.40 $16,877.60
Disclosure

SEC source: 0001104659-20-043285 · tm2014981d3_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,319

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
February 23, 2020 Filed Feb 24, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 319 $94.99 $30,301.81
Disclosure

SEC source: 0001104659-20-024371 · tm2010776d1_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,608

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
January 23, 2020 Filed Jan 27, 2020 19:05 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantOption to Purchase Common Stock · Derivative 17,400 $0.00 Strike: $99.66 $0.00
Disclosure

SEC source: 0001104659-20-007264 · tm205922d5_4.xml · derivative · entry 2

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,400

Underlying: Common Stock · 17,400 shares

Expires 2030-01-23

F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.

Read SEC document
January 23, 2020 Filed Jan 27, 2020 19:05 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 10,600 $0.00 $0.00
Disclosure

SEC source: 0001104659-20-007264 · tm205922d5_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,927

F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020.

Read SEC document
January 01, 2020 Filed Jan 3, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 334 $123.92 $41,389.28
Disclosure

SEC source: 0001104659-20-001090 · tm201209d7_4.xml · nonDerivative · entry 2

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,327

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
December 31, 2019 Filed Jan 3, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 1,151 $123.92 $142,631.92
Disclosure

SEC source: 0001104659-20-001090 · tm201209d7_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,661

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
November 23, 2019 Filed Nov 26, 2019 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 460 $88.89 $40,889.40
Disclosure

SEC source: 0001104659-19-067741 · tm1923933d1_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,812

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:03 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 417 $65.87 $27,467.79
Disclosure

SEC source: 0001144204-19-047224 · tv530564_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,272

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
August 23, 2019 Filed Aug 27, 2019 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 319 $60.90 $19,427.10
Disclosure

SEC source: 0001144204-19-041878 · tv528285_4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,689

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
July 01, 2019 Filed Jul 3, 2019 17:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 289 $79.17 $22,880.13
Disclosure

SEC source: 0001144204-19-033814 · tv524733_form4.xml · nonDerivative · entry 1

Durso Jerome Benedict · CIK 0001698665 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,008

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.